Specific binding of 3H-SCH 23390 to dopamine D1 receptors in vivo.
The binding of 3H-SCH 23390 was studied in vivo in the mouse brain. The binding was saturable, reversible and stereospecific. The level of nonspecific binding was 5-15% of total binding. Pharmacological characterization revealed binding of 3H-SCH 23390 to D1 receptors. Thus, dopaminergic antagonists known to possess D1 affinity, e.g., SCH 23390 itself, cis-flupentixol and (+)-butaclamol, were potent inhibitors of the 3H-SCH 23390 binding. On the other hand, high doses of D2 selective compounds were required to inhibit the 3H-SCH 23390 binding. These results indicate that 3H-SCH 23390 is a ligand of choice for in vivo studies of D1 receptors.
Andersen
P H
PH
Grønvald
F C
FC
D000818:Animals; D014150:Antipsychotic Agents / Q000378:metabolism*; D001552:Benzazepines / Q000378:metabolism*; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011485:Protein Binding; D011954:Receptors, Dopamine / Q000302:isolation & purification / Q000378:metabolism*; D017447:Receptors, Dopamine D1; D014018:Tissue Distribution; D014316:Tritium
D014150:Antipsychotic Agents; D001552:Benzazepines; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D014316:Tritium